1例糖皮质激素致严重低钾的微小病变型肾病患者的药学实践

中国药物警戒 ›› 2019, Vol. 16 ›› Issue (7): 425-429.

• 安全性评价与合理用药 • 上一篇下一篇

1例糖皮质激素致严重低钾的微小病变型肾病患者的药学实践

杨虹¹, 尹冬虹^2,*

1 太原市中心医院药剂科,山西太原030000;
2 山西医科大学第二医院药学部,山西太原030000

收稿日期:2019-04-18 修回日期:2019-08-06 出版日期:2019-07-20 发布日期:2019-08-06
通讯作者: 尹冬虹,女,主管药师,临床药学。E-mail：13903430239@126.com
作者简介:杨虹,女,主管药师,临床药学。
基金资助:
山西省卫生计生委青年课题（201601055）：肾病综合征患者药学服务体系的建立及服务效果的研究

Pharmaceutical Practice of One Case of Severe Hypokalemia Induced by Glucocorticoid in Patient with Minimal Change Nephropathy

YANG Hong¹, YIN Donghong^2,*

1 Department of Pharmacy, Taiyuan Central Hospital, Shanxi Taiyuan 030000, China;
2 Department of Pharmacy, Second Hospital of Shanxi Medical University, Shanxi Taiyuan 030000, China

Received:2019-04-18 Revised:2019-08-06 Online:2019-07-20 Published:2019-08-06

摘要/Abstract

摘要： 目的介绍临床糖皮质激素致严重低钾的微小病变型肾病的药学实践。方法针对具体的案例,参与糖皮质激素致低钾血症患者免疫抑制治疗方案的个体化设计,并提出药学干预建议,保证患者安全有效用药。结果临床药师发挥所长,参与方案制定,加强药学监护,保证了患者的治疗效果。结论加强对于糖皮质激素致严重低钾的微小病变型肾病患者的药学监护,提高用药安全性、有效性和合理性。

关键词: 临床药师, 糖皮质激素, 低钾血症, 微小病变

Abstract: Objective To introduce the pharmaceutical practice in a minimal change nephropathy patient with severe hypokalemia induced by glucocorticoid in clinical setting. Methods For a specific case, the clinical pharmacists participated in the individualized design of immunosuppressive therapy for a patient with glucocorticoid-induced hypokalemia, and put forward suggestions for pharmaceutical intervention to ensure safe and effective medication for patients. Results Clinical pharmacists participated in deciding the treatment and strengthened pharmaceutical care by playing their strengths, thus the therapeutic effect of the patient was ensured. Conclusion The safety, effectiveness and rationality of the drug use can be improved by strengthening the pharmaceutical care for minimal change nephropathy patients with severe hypokalemia induced by glucocorticoids.

Key words: clinical pharmacist, glucocorticoid, hypokalemia, minimal change disease

中图分类号:

R977.1

杨虹, 尹冬虹. 1例糖皮质激素致严重低钾的微小病变型肾病患者的药学实践[J]. 中国药物警戒, 2019, 16(7): 425-429.

YANG Hong, YIN Donghong. Pharmaceutical Practice of One Case of Severe Hypokalemia Induced by Glucocorticoid in Patient with Minimal Change Nephropathy[J]. Chinese Journal of Pharmacovigilance, 2019, 16(7): 425-429.

参考文献

[1] Vivarelli M,Massella L,Ruggiero B,et.al. Minimal Change Disease[J]. Clin J Am SocNephrol. 2017,12(2):332-345.
[2] Rovin B H,Caster D J,Cattran D C,et al.Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference[J].Kidney Int, 2019,95(2):281-295.
[3] Korbet S M,Whittier W L.Management of Adult Minimal Change Disease[J]. Clinical Journal of the American Society of Nephrology,2019,14(6):911-913.
[4] Cattran D C,Feehally J,Cook H T,et al.Kidney Disease Improving Global Outcomes Glomerulonephritis Work Group: KDIGO clinical practice guideline for glomerulon-
phritis[J]. Kidney International Supplements,2012, 2(2): 139-274.
[5] Hogan J,Radhakrishnan J.The treatment of minimal change disease in adults[J]. J Am Soc Nephrol,2013,24(5): 702-711.
[6] Palmer S C,Nand K,Strippoli G F M. Interventions for minimal change disease in adults with nephrotic syndrome[J]. Cochrane Database Syst Rev, 2008,(1):2-10.
[7] Hwang Y G,Saag K.The safety of low-dose glucocorticoids in rheumatic diseases: results from observational studies[J]. Neuroimmunomodulation,2015,22(1-2):72-82.
[8] Ke Q,He F,Lu L,et al.The R900S mutation in CACNA1S associated with hypokalemic periodic paralysis[J]. Neuro-
muscul Disord,2015,25(12):955-957.
[9] Finsterer J.Primary periodic paralyses[J]. Acta Neurol Scand, 2008,117(3):145-158.
[10] Lin S H,Huang C L.Mechanism of thyrotoxic periodic paralysis[J]. Journal of the American Society of Nephrology, 2012, 23(6):985-988.
[11] Arzel-Hézode M,McGoey S,Sternberg D,et al.Glucocorticoids may trigger attacks in several types of periodic paralysis[J].Neuromuscul disord,2009,19(3): 217-219.
[12] Poulin H,Gosselin-Badaroudine P,Vicart S,et al.Substitutions of the S4DIV R2 residue (R1451) in Na V 1.4 lead to complex forms of paramyotonia congenita and periodic paralyses[J]. Sci Rep, 2018 ,8(1):2041.
[13] 王兆平, 高峰, 刘洁一,等.糖皮质激素低钾性麻痹与原发性低钾性麻痹比较研究[J].河北医药, 2015, 37(6):877-879.
[14] Levitt J O.Practical aspects in the management of hypokalemic periodic paralysis[J]. Journal of translational medicine, 2008,6(1):1-8.
[15] Weber F, Jurkat-Rott K, Lehmann-Horn F. Hyperkalemic periodic paralysis[J/OL].(2003-07-18)[2016-01-28]. https://www.ncbi.nlm.nih.gov/books/NBK1496/.
[16] Kasper D,Fauci A,Hauser S,el al. Harrison's Principles of Internal Medicine[M]. 19th ed. New York: McGraw-
Hill Education,2015.
[17] Teagarden C M, Picardo C W.Betamethasone-induced hypokalemic periodic paralysis in pregnancy[J]. Obstetrics & Gynecology, 2011, 117(2): 433-435.
[18] Lapie P,Lory P,Fontaine B.Hypokalemic periodic paralysis: an autosomal dominant muscle disorder caused by mutations in a voltage-gated calcium channel[J]. Neurom-
uscul Disord, 1997,7(4):234-400.
[19] Lewis K L,Malouff T D,Kesler A M,el al. Hypokalemic Periodic Paralysis- the importance of patient education[J]. Rom J Intern Med ,2019,(1):1-8.
[20] 陈瑶. 泼尼松致30例不良反应文献分析[J].中国药物警戒,2010,7(10):626-628.
[21] 张凯, 童荣, 倪娟, 等.1次静滴地塞米松诱发低钾性麻痹例[J].西南国防医药,2017,27(8):898-898.
[22] 钟林清, 许名远, 许慈萱, 等.宁德地区低钾型周期性麻痹152例诱因分析[J].中国实用医药, 2015, 10(8):114-115.
[23] 司继刚. 地塞米松注射液临床应用安全性分析评价[J]. 中国药学杂志,2016,51(22):1972-1975.
[24] 李志金, 杨赞章, 李善学.甲泼尼龙致低钾性麻痹2例[J].医药导报, 2015,34(8):1117-1118.
[25] 张永兰, 程岩, 王桂萍, 等.突发性聋患者口服甲泼尼龙致低钾麻痹一例[J].中华耳鼻咽喉头颈外科杂志, 2016, 51(10):783-784.
[26] 李群,胡怀岭,刘尚,等.低钾血症118 例心电图分析[J]. 岭南急诊医学杂志,2014,19(3): 220-221.

1例糖皮质激素致严重低钾的微小病变型肾病患者的药学实践

Pharmaceutical Practice of One Case of Severe Hypokalemia Induced by Glucocorticoid in Patient with Minimal Change Nephropathy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	范凯凯, 王聪, 刘洪峰, 王西勇. 临床药师对某院丙氨酰谷氨酰胺注射液应用干预分析[J]. 中国药物警戒, 2024, 21(2): 181-184.
[2]	陈婕, 秦侃. 肠外营养个体化给药实践评价[J]. 中国药物警戒, 2023, 20(7): 812-816.
[3]	刘婧, 夏亮, 张世杰. 1例多元药物过敏急性胰腺炎患者行药物激发试验的药学监护[J]. 中国药物警戒, 2023, 20(7): 822-824.
[4]	贾兆广, 徐文帅, 季丽娜, 王琳琳, 赵丽娜, 赵景全, 牟向东. 儿童肺炎支原体肺炎的临床诊疗及相关药物合理使用[J]. 中国药物警戒, 2023, 20(12): 1391-1395.
[5]	苏甦, 伍诗琪, 张青霞, 闫素英. 1例吲达帕胺致粒细胞缺乏症患者的药学监护[J]. 中国药物警戒, 2023, 20(11): 1282-1285.
[6]	卫红涛, 沈素, 李丹丹, 廖音. 705例神经内科问题医嘱的帕累托图分析[J]. 中国药物警戒, 2022, 19(8): 900-903.
[7]	原小陇, 万齐华, 陶东红, 祁浩, 王爱霞. 1例甲氨蝶呤片严重中毒患者的药学监护[J]. 中国药物警戒, 2022, 19(8): 924-928.
[8]	孙雪林, 张攀, 胡欣. 1例维得利珠单抗治疗重症溃疡性结肠炎的药学监护[J]. 中国药物警戒, 2022, 19(7): 782-785.
[9]	唐静雅. 临床药师参与1例肠外营养相关性肝损伤治疗的药学监护[J]. 中国药物警戒, 2022, 19(7): 786-788.
[10]	王春婷, 文雯. 甘草酸二铵致药源性低钾血症报告情况及影响因素分析[J]. 中国药物警戒, 2022, 19(5): 532-536.
[11]	杨宝春, 孙欣, 杨欣, 吴琳, 王丽萍. 临床药师参与1例尿路感染伴药物热患者药学实践[J]. 中国药物警戒, 2022, 19(5): 572-573.
[12]	陈方方, 张红旭. 大剂量甲氨蝶呤治疗原发性中枢神经系统淋巴瘤的药学实践[J]. 中国药物警戒, 2022, 19(4): 446-449.
[13]	卫克昭, 吴欢, 张子旭, 冯加华, 高建平. 小鼠大剂量糖皮质激素不良反应的性别差异性研究[J]. 中国药物警戒, 2022, 19(3): 248-251.
[14]	杨桂玲, 赵牡丹, 高义玲, 王贝, 朱明辉. 莫西沙星注射液致低血钾1例分析[J]. 中国药物警戒, 2022, 19(3): 342-344.
[15]	汪乐尘, 沈爱宗. 安徽省某三甲医院伏立康唑致低钾血症不良反应分析[J]. 中国药物警戒, 2022, 19(11): 1238-1241.